{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Tirzepatide?<\/h3>\n<p style=\"margin: 0;\"><strong>Tirzepatide<\/strong> je 39-aminokyselinov\u00fd du\u00e1ln\u00ed agonista receptor\u016f GLP-1 a GIP a aktivn\u00ed v\u00fdzkumn\u00e1 molekula stoj\u00edc\u00ed za p\u0159\u00edpravky Mounjaro a Zepbound. V sou\u010dasn\u00fdch publikovan\u00fdch studi\u00edch vykazuje nejv\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost a glyk\u00e9mii ze v\u0161ech peptid\u016f, p\u0159i\u010dem\u017e du\u00e1ln\u00ed receptorov\u00fd profil poskytuje v\u00fdrazn\u011b siln\u011bj\u0161\u00ed odpov\u011b\u010f ne\u017e jednotliv\u00e9 agonisty GLP-1 v p\u0159\u00edm\u00fdch srovn\u00e1vac\u00edch studi\u00edch, jako je SURPASS-2. Polo\u010das v plazm\u011b je p\u0159ibli\u017en\u011b 120 hodin (~5 dn\u00ed), co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch vialk\u00e1ch o obsahu 5 mg a\u017e 120 mg v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item2<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, kostra zalo\u017een\u00e1 na GIP s Aib<sup>2<\/sup>, Aib<sup>13<\/sup>,  a Lys<sup>20<\/sup>-C20 mastn\u00e1 diacylace p\u0159es \u03b3Glu-\u03b3Glu spacer)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je Tirzepatide?<\/h2>\n<p><strong>Tirzepatide<\/strong> je 39-aminokyselinov\u00fd du\u00e1ln\u00ed agonista inkretenov\u00fdch receptor\u016f, kter\u00fd aktivuje jak receptor pro glukagonu podobn\u00fd peptid-1 (GLP-1), tak receptor pro gluk\u00f3zo-dependentn\u00ed inzulinotropn\u00ed polypeptid (GIP) se srovnatelnou \u00fa\u010dinnost\u00ed. Vyvinut\u00fd spole\u010dnost\u00ed Eli Lilly a zve\u0159ejn\u011bn\u00fd v roce 2018 se stal prvn\u00edm du\u00e1ln\u00edm agonistou inkreten\u016f, kter\u00fd z\u00edskal regula\u010dn\u00ed schv\u00e1len\u00ed (Mounjaro pro diabetes 2. typu v roce 2022, Zepbound pro chronickou kontrolu hmotnosti v roce 2023). Tirzepatide je zalo\u017een na peptidov\u00e9 kost\u0159e GIP \u2014 nikoli na kost\u0159e GLP-1, kterou pou\u017e\u00edv\u00e1 semaglutid \u2014 se dv\u011bma substitucemi \u03b1-aminoisom\u00e1seln\u00e9 kyseliny (Aib) na pozic\u00edch 2 a 13, kter\u00e9 odol\u00e1vaj\u00ed \u0161t\u011bpen\u00ed DPP-4, a C20 mastnou dikyselinou p\u0159ipojenou k lysinu 20 p\u0159es dva \u03b3-glutamov\u00e9 spacery. Acylov\u00fd \u0159et\u011bzec C20 je o jeden uhl\u00edk del\u0161\u00ed ne\u017e C18 u semaglutidu, co\u017e vede k t\u011bsn\u011bj\u0161\u00ed vazb\u011b na albumin a m\u00edrn\u011b odli\u0161n\u00e9mu farmakokinetick\u00e9mu profilu.<\/p>\n<p>Dob\u0159e charakterizovan\u00e1 struktura tirzepatidu m\u00e1 empirick\u00fd vzorec C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> s pr\u016fm\u011brnou molekulovou hmotnost\u00ed 4813,45 Da. Polo\u010das v plazm\u011b je p\u0159ibli\u017en\u011b 120 hodin (~5 dn\u00ed), co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed subkut\u00e1nn\u00ed d\u00e1vkov\u00e1n\u00ed v publikovan\u00fdch studi\u00edch. L\u00e1tka je dod\u00e1v\u00e1na jako vysoce \u010dist\u00fd lyofilizovan\u00fd pr\u00e1\u0161ek pro rekonstituci s bakteriostatickou vodou. Farmaceutick\u00fd tirzepatid (Mounjaro, Zepbound) je schv\u00e1len FDA pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed pod v\u00fdrobn\u00ed kontrolou spole\u010dnosti Eli Lilly; v\u00fdzkumn\u00fd tirzepatid prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n <strong>ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed schv\u00e1leno FDA pro pod\u00e1v\u00e1n\u00ed lidem nebo zv\u00ed\u0159at\u016fm. Pro \u0161ir\u0161\u00ed v\u00fdzkum inkretin\u016f nav\u0161tivte na\u0161e <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> produktov\u00e9 str\u00e1nky.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 du\u00e1ln\u00ed agonismus receptor\u016f GLP-1\/GIP<\/h2>\n<p>Co odli\u0161uje tirzepatid od d\u0159\u00edv\u011bj\u0161\u00edch jednoinkretinov\u00fdch peptid\u016f, je jeho <strong>vyv\u00e1\u017een\u00e1 koaktivace dvou odli\u0161n\u00fdch receptor\u016f<\/strong>, z nich\u017e ka\u017ed\u00fd p\u0159isp\u00edv\u00e1 komplement\u00e1rn\u00edmi metabolick\u00fdmi efekty pozorovan\u00fdmi v publikovan\u00fdch v\u00fdzkumech:<\/p>\n<ul>\n<li><strong>Aktivace receptoru GLP-1 \u2014 sytost, sekrece inzulinu \u03b2-bu\u0148kami, vyprazd\u0148ov\u00e1n\u00ed \u017ealudku<\/strong> \u2014 Tirzepatid se v\u00e1\u017ee na receptor GLP-1 s afinitou srovnatelnou s p\u0159irozen\u00fdm GLP-1, aktivuje G\u03b1<sub>s<\/sub>-v\u00e1zanou adenyl\u00e1tcykl\u00e1zu a n\u00e1slednou cAMP\/PKA signalizaci. To vytv\u00e1\u0159\u00ed kanonick\u00e9 efekty GLP-1: gluk\u00f3za-dependentn\u00ed potenciace sekrece inzulinu z pankreatick\u00fdch \u03b2-bun\u011bk, potla\u010den\u00ed glukagonu z \u03b1-bun\u011bk, zpomalen\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a centr\u00e1ln\u00ed efekty potla\u010den\u00ed chuti k j\u00eddlu prost\u0159ednictv\u00edm neuron\u016f POMC v nucleus arcuatus. Tato slo\u017eka se p\u0159ekr\u00fdv\u00e1 s mechanismem semaglutidu.<\/li>\n<li><strong>Aktivace receptoru GIP \u2014 lipol\u00fdza adipocyt\u016f, energetick\u00fd v\u00fddej, podpora \u03b2-bun\u011bk<\/strong> \u2014 Komponenta GIP je t\u00edm, co \u010din\u00ed tirzepatid farmakologicky odli\u0161n\u00fdm. Aktivace receptoru GIP zvy\u0161uje sekreci inzulinu gluk\u00f3za-dependentn\u00edm zp\u016fsobem (dopl\u0148kov\u011b k efektu GLP-1), ale tak\u00e9 p\u016fsob\u00ed na adipocyty, aby podporoval lipol\u00fdzu v podm\u00ednk\u00e1ch hladov\u011bn\u00ed, zat\u00edmco v syt\u00e9m stavu podporuje ukl\u00e1d\u00e1n\u00ed triglycerid\u016f. V\u00fdzkum nazna\u010duje, \u017ee signalizace p\u0159es receptor GIP tak\u00e9 m\u00edrn\u011b zvy\u0161uje klidov\u00fd energetick\u00fd v\u00fddej a p\u016fsob\u00ed v oblastech CNS odli\u0161n\u00fdch od GLP-1, v\u010detn\u011b dorsomedi\u00e1ln\u00edho hypotalamu. \u010cist\u00fdm efektem je aditivn\u00ed sign\u00e1l t\u011blesn\u00e9 hmotnosti p\u0159esahuj\u00edc\u00ed to, co produkuje samotn\u00fd GLP-1.<\/li>\n<li><strong>Vyv\u00e1\u017een\u00ed receptor\u016f a strukturn\u00ed optimalizace<\/strong> \u2014 V testech vazby radioligand\u016f vykazuje tirzepatid vy\u0161\u0161\u00ed afinitu k receptoru GIP ne\u017e k receptoru GLP-1 \u2014 neobvykl\u00fd pom\u011br, kter\u00fd jej odli\u0161uje od d\u0159\u00edv\u011bj\u0161\u00edch kandid\u00e1t\u016f na du\u00e1ln\u00ed agonisty. Asymetrie je z\u00e1m\u011brn\u00e1: kostra GIP umo\u017e\u0148uje vy\u0161\u0161\u00ed \u00fa\u010dinnost na receptor GIP, zat\u00edmco modifikace zachov\u00e1vaj\u00ed dostate\u010dnou aktivitu GLP-1. Tirzepatid je n\u011bkdy popisov\u00e1n jako \u201cGIP-biasovan\u00fd\u201d ve farmakologii receptor\u016f, co\u017e m\u00e1 implikace pro diferenci\u00e1ln\u00ed signalizaci pozorovanou ve v\u00fdzkumn\u00fdch modelech.<\/li>\n<\/ul>\n<p>C20 mastn\u00e1 diacylov\u00e1 vazba na lysinu 20 se reverzibiln\u011b v\u00e1\u017ee na cirkuluj\u00edc\u00ed s\u00e9rov\u00fd albumin, \u010d\u00edm\u017e vytv\u00e1\u0159\u00ed peptidov\u00e9 depot, kter\u00e9 chr\u00e1n\u00ed tirzepatid p\u0159ed ren\u00e1ln\u00ed clearance a zaji\u0161\u0165uje plazmatick\u00fd polo\u010das ~120 hodin. Dvojit\u00e1 substituce Aib (pozice 2 a 13) zabra\u0148uje \u0161t\u011bpen\u00ed DPP-4 na dvou odli\u0161n\u00fdch m\u00edstech, poskytuj\u00edc\u00ed redundantn\u00ed proteolytickou ochranu. Spole\u010dn\u011b tyto strukturn\u00ed vlastnosti p\u0159em\u011b\u0148uj\u00ed to, co by jinak byl kr\u00e1tkodob\u011b p\u016fsob\u00edc\u00ed inkretinov\u00fd peptid, na v\u00fdzkumn\u00fd peptid s t\u00fddenn\u00edm pod\u00e1v\u00e1n\u00edm.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>Tirzepatid se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu ke studiu:<\/p>\n<ul>\n<li><strong>Kontroly glyk\u00e9mie a inzulinov\u00e9 senzitivity<\/strong> \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed se semaglutidem a dal\u0161\u00edmi monoagonisty GLP-1 (Frias et al., NEJM 2021 SURPASS-2); modely db\/db, ZDF a my\u0161\u00ed na vysokotu\u010dn\u00e9 diet\u011b; \u00fa\u010dinky na n\u00e1hradn\u00ed markery HbA1c, hladinu gluk\u00f3zy nala\u010dno a parametry hyperinzulinemicko-euglykemick\u00e9ho clampu<\/li>\n<li><strong>V\u00fdzkumu t\u011blesn\u00e9 hmotnosti a obezity<\/strong> \u2014 studie SURMOUNT-1 prok\u00e1zala ~22% sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti p\u0159i d\u00e1vce 15 mg t\u00fddn\u011b po dobu 72 t\u00fddn\u016f, co\u017e p\u0159edstavuje nejv\u011bt\u0161\u00ed \u00fa\u010dinek jednotliv\u00e9ho peptidu zaznamenan\u00fd v klinick\u00e9m v\u00fdzkumu; modely dietou indukovan\u00e9 obezity u hlodavc\u016f, t\u011blesn\u00e9 slo\u017een\u00ed (DEXA\/MRI), respira\u010dn\u00ed kvocient<\/li>\n<li><strong>MASLD\/MASH (metabolicky asociovan\u00e9 jatern\u00ed onemocn\u011bn\u00ed)<\/strong> \u2014 obsah jatern\u00edch triglycerid\u016f, ALT\/AST, staging fibr\u00f3zy; data ze studie SYNERGY-NASH<\/li>\n<li><strong>Kardiovaskul\u00e1rn\u00ed v\u00fdzkum<\/strong> \u2014 \u00fa\u010dinky na krevn\u00ed tlak, lipidov\u00e9 profily, progresi ateroskler\u00f3zy u ApoE<sup>-\/-<\/sup> modelech; data kardiovaskul\u00e1rn\u00edch v\u00fdsledk\u016f ze studie SURPASS-CVOT<\/li>\n<li><strong>V\u00fdzkum sp\u00e1nkov\u00e9 apnoe<\/strong> \u2014 z\u00e1va\u017enost obstruk\u010dn\u00ed sp\u00e1nkov\u00e9 apnoe, index apnoe-hypopnoe v datasetu SURMOUNT-OSA<\/li>\n<li><strong>Ren\u00e1ln\u00ed ochrana u model\u016f diabetick\u00e9 nefropatie<\/strong> \u2014 albuminurie, glomerul\u00e1rn\u00ed filtrace, expanze mezangi\u00e1ln\u00edch bun\u011bk u streptozotocinem indukovan\u00e9ho a u Akita my\u0161\u00edho modelu diabetick\u00e9ho onemocn\u011bn\u00ed ledvin<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum inkretinov\u00fdch peptid\u016f<\/strong> \u2014 benchmark pro srovn\u00e1n\u00ed dual-agonist\u016f vs single-agonist\u016f vs triple-agonist\u016f. Vizte na\u0161e <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-vs-tirzepatide\/\">P\u0159\u00edru\u010dka Retatrutide vs Tirzepatide<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> produktov\u00e1 str\u00e1nka pro sourozeneck\u00e9 kompar\u00e1tory.<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext, kam Tirzepatide zapad\u00e1 v r\u00e1mci metabolicko-peptidov\u00e9 krajiny, vizte <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (triple GLP-1\/GIP\/glukagon agonista, kompar\u00e1tor nov\u00e9 generace) a <a href=\"https:\/\/medsbase.com\/cs\/ozempic-vs-mounjaro\/\">na\u0161e p\u0159\u00edru\u010dka Ozempic vs Mounjaro<\/a>. Prohl\u00e9dn\u011bte si kompletn\u00ed <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f<\/a> pro p\u0159\u00edbuzn\u00e9 slou\u010deniny.<\/p>\n<h2>Dostupn\u00e9 s\u00edly a koncentrace<\/h2>\n<p>MedsBase nab\u00edz\u00ed Tirzepatide v jeden\u00e1cti lyofilizovan\u00fdch d\u00e1vkov\u00fdch sil\u00e1ch pokr\u00fdvaj\u00edc\u00edch cel\u00e9 v\u00fdzkumn\u00e9 d\u00e1vkovac\u00ed spektrum od pilotn\u00edho d\u00e1vkov\u00e1n\u00ed po v\u00edcem\u011bs\u00ed\u010dn\u00ed hromadn\u00e9 protokoly. Ka\u017ed\u00e1 s\u00edla je dostupn\u00e1 v balen\u00ed po 10 nebo 20 vialech s kompletn\u00edm n\u00e1vodem k rekonstituci:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00fd v\u00fdzkumn\u00fd p\u0159\u00edpad u\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pilotn\u00ed d\u00e1vkov\u00e1n\u00ed, n\u00edzk\u00e1 titrace, kr\u00e1tk\u00e9 cykly<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdzkumn\u00e1 s\u00edla pro udr\u017eovac\u00ed d\u00e1vkov\u00e1n\u00ed, st\u0159edn\u00ed titrace<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Klinicky ekvivalentn\u00ed c\u00edlov\u00e1 s\u00edla (maxim\u00e1ln\u00ed schv\u00e1len\u00e1 lidsk\u00e1 d\u00e1vka)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdzkumn\u00e1 v\u011btev s vysokou d\u00e1vkou, pr\u016fzkumn\u00e9 protokoly<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00edce t\u00fddenn\u00ed protokoly z jedn\u00e9 lahvi\u010dky, ni\u017e\u0161\u00ed objem rekonstituce<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdzkum s prodlou\u017een\u00fdm cyklem, ni\u017e\u0161\u00ed cena za mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00edce m\u011bs\u00ed\u010dn\u00ed protokoly, srovn\u00e1vac\u00ed v\u00fdzkum d\u00e1vkov\u00e9 odpov\u011bdi<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdzkumn\u00e1 v\u011btev pro srovn\u00e1n\u00ed vysok\u00fdch d\u00e1vek<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hromadn\u00e1 v\u00fdzkumn\u00e1 lahvi\u010dka, n\u00edzk\u00e1 cena za mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Studie s v\u00edce kohortami, v\u00edce m\u011bs\u00ed\u010dn\u00ed protokoly<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maxim\u00e1ln\u00ed hromadn\u00e1 v\u00fdzkumn\u00e1 lahvi\u010dka, nejni\u017e\u0161\u00ed cena za mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>V\u0161ech jeden\u00e1ct sil je stejn\u00e9 chemick\u00e9 formy (lyofilizovan\u00fd pr\u00e1\u0161ek, HPLC \u010distota 99%+). Lahvi\u010dky s vy\u0161\u0161\u00edm obsahem mg vy\u017eaduj\u00ed men\u0161\u00ed objem rekonstituce na jednotku d\u00e1vky, co\u017e je u\u017eite\u010dn\u00e9 pro v\u00fdzkumn\u00edky minimalizuj\u00edc\u00ed objem injekce nebo prov\u00e1d\u011bj\u00edc\u00ed prodlou\u017een\u00e9 v\u00edce m\u011bs\u00ed\u010dn\u00ed protokoly z jedn\u00e9 lahvi\u010dky. Proto\u017ee rekonstituovan\u00fd roztok je stabiln\u00ed po dobu ~30 dn\u016f, optim\u00e1ln\u00ed velikost lahvi\u010dky pro dan\u00fd protokol z\u00e1vis\u00ed na t\u00fddenn\u00ed d\u00e1vce \u00d7 kompromisu t\u00fddn\u016f na lahvi\u010dku.<\/p>\n<h2>Srovn\u00e1n\u00ed \u2014 Tirzepatide vs Semaglutide vs Retatrutide<\/h2>\n<p>Tirzepatide se nach\u00e1z\u00ed v centru modern\u00edho v\u00fdzkumu inkretinov\u00fdch agonist\u016f, mezi jednoduch\u00fdm receptorem <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> (pouze GLP-1) a trojit\u00fdm receptorem <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (GLP-1 + GIP + glukagon). Ka\u017ed\u00fd krok po \u017eeb\u0159\u00ed\u010dku receptor\u016f p\u0159in\u00e1\u0161\u00ed progresivn\u011b v\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost v p\u0159\u00edm\u00e9m v\u00fdzkumu, ale tak\u00e9 \u0161ir\u0161\u00ed syst\u00e9movou signalizaci.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil receptoru<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (jednoduch\u00fd agonista)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (du\u00e1ln\u00ed agonista)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glukagon (trojit\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peptidov\u00e1 kostra<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP-podobn\u00fd (39 aa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Polo\u010das<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 hodin (~7 dn\u00ed)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~120 hodin (~5 dn\u00ed)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dn\u00ed<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mastn\u00e1 kyselina s nav\u00e1zanou skupinou<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 dikyselina + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 dikyselina + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 dikyselina + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Referen\u010dn\u00ed zna\u010dka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Experiment\u00e1ln\u00ed (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typick\u00e1 t\u00fddenn\u00ed v\u00fdzkumn\u00e1 d\u00e1vka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132,4 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2,5\u201315 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u00da\u010dinek na t\u011blesnou hmotnost v klinick\u00fdch studi\u00edch<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15 % (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22 % (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24 % (f\u00e1ze 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nejsiln\u011bj\u0161\u00ed v\u00fdzkumn\u00fd sign\u00e1l<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kontrola glyk\u00e9mie, kardiovaskul\u00e1rn\u00ed<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kombinovan\u00e1 kontrola glyk\u00e9mie a t\u011blesn\u00e9 hmotnosti, MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nejv\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Studie p\u0159\u00edm\u00e9ho porovn\u00e1n\u00ed SURPASS-2 (Frias et al., NEJM 2021) prok\u00e1zala nad\u0159azenost tirzepatidu 15 mg oproti semaglutidu 1 mg v redukci HbA1c a t\u011blesn\u00e9 hmotnosti b\u011bhem 40 t\u00fddn\u016f \u2013 jeden z nejrozs\u00e1hlej\u0161\u00edch soubor\u016f dat p\u0159\u00edm\u00e9ho porovn\u00e1n\u00ed ve v\u00fdzkumu inkretin\u016f. Pro metodologick\u00e9 detaily o dual- versus triple-agonistick\u00e9m p\u0159\u00edstupu si p\u0159e\u010dt\u011bte <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-vs-tirzepatide\/\">Retatrutid vs Tirzepatid: triple versus dual agonista<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. V\u00fdzkumn\u00edci vyb\u00edraj\u00edc\u00ed mezi t\u011bmito peptidy obvykle zva\u017euj\u00ed selektivitu receptor\u016f (\u010dist\u0161\u00ed farmakologie u semaglutidu), velikost \u00fa\u010dinku (v\u011bt\u0161\u00ed u tirzepatidu a retatrutidu) a s\u00edlu dostupn\u00fdch klinick\u00fdch dat (rozs\u00e1hl\u00e1 pro semaglutid a tirzepatid, st\u00e1le se rozv\u00edjej\u00edc\u00ed pro retatrutid).<\/p>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> lyofilizovan\u00e9 lahvi\u010dky skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu pro kr\u00e1tkodob\u00e9 pracovn\u00ed z\u00e1soby. Pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch lahvi\u010dek zmrazte p\u0159i \u221220 \u00b0C. Lyofilizovan\u00fd tirzepatid je stabiln\u00ed v chladni\u010dce a\u017e 24 m\u011bs\u00edc\u016f a p\u0159i \u221220 \u00b0C a\u017e 36 m\u011bs\u00edc\u016f. Vyvarujte se cykl\u016fm zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed lyofilizovan\u00e9ho pr\u00e1\u0161ku.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> injektujte bakteriostatickou vodu po bo\u010dn\u00ed st\u011bn\u011b lahvi\u010dky s peptidem (ne p\u0159\u00edmo na lyofilizovan\u00fd kol\u00e1\u010d). Pro lahvi\u010dku 10 mg odpov\u00edd\u00e1 2,0 ml bakteriostatick\u00e9 vody pracovn\u00ed koncentraci 5 mg\/ml \u2013 10 d\u00edlc\u016f na inzul\u00ednov\u00e9 st\u0159\u00edka\u010dce U-100 odpov\u00edd\u00e1 500 mcg. Jemn\u011b zakru\u017ete \u2013 <strong>ne<\/strong> net\u0159epejte \u2013 a nechte 2\u20135 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed. Spr\u00e1vn\u011b rekonstituovan\u00fd roztok by m\u011bl b\u00fdt \u010dir\u00fd a bezbarv\u00fd.<\/p>\n<p><strong>Po rekonstituci:<\/strong> skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu. Rekonstituovan\u00fd roztok nezmrazujte \u2013 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed degraduj\u00ed integritu peptidu. Zlikvidujte jakoukoli lahvi\u010dku projevuj\u00edc\u00ed z\u00e1kal, sra\u017eeniny nebo zm\u011bnu barvy. Proto\u017ee se tirzepatid ve v\u00fdzkumn\u00fdch protokolech d\u00e1vkuje jednou t\u00fddn\u011b, jedna rekonstituovan\u00e1 lahvi\u010dka 10 mg obvykle pokryje 2\u20134 t\u00fddny d\u00e1vkov\u00e1n\u00ed v z\u00e1vislosti na c\u00edlov\u00e9 d\u00e1vce; lahvi\u010dka 50 mg pokryje 10\u201320 t\u00fddn\u016f p\u0159i klinicky ekvivalentn\u00edch d\u00e1vk\u00e1ch.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>K \u010demu se pou\u017e\u00edv\u00e1 Tirzepatid ve v\u00fdzkumu?<\/h3>\n<p>Tirzepatid se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zam\u011b\u0159en\u00e9m na glykemickou kontrolu, inzulinovou senzitivitu, t\u011blesnou hmotnost a adipozitu, jatern\u00ed onemocn\u011bn\u00ed MASLD\/MASH, kardiovaskul\u00e1rn\u00ed parametry, sp\u00e1nkovou apnoe a diabetickou nefropatii. Jde o nejl\u00e9pe charakterizovan\u00e9ho dvojit\u00e9ho agonistu GLP-1\/GIP a standardn\u00ed kompar\u00e1tor pro nov\u011bj\u0161\u00ed v\u00fdzkum multiagonistick\u00fdch peptid\u016f. V\u00fdzkumn\u00fd tirzepatid prod\u00e1van\u00fd zde je <strong>ne<\/strong> schv\u00e1len FDA pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed a dod\u00e1v\u00e1 se v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<h3>Jak se Tirzepatid li\u0161\u00ed od Semaglutidu?<\/h3>\n<p>Struktur\u00e1ln\u00ed rozd\u00edl je v receptorov\u00e9m profilu a peptidov\u00e9 kost\u0159e. Tirzepatid je postaven na 39-aminokyselinov\u00e9 kost\u0159e GIP a koaktivuje receptory GIP i GLP-1. Semaglutid je postaven na 31-aminokyselinov\u00e9 kost\u0159e GLP-1 a aktivuje pouze receptor GLP-1. GIP slo\u017eka v tirzepatidu p\u0159id\u00e1v\u00e1 lipol\u00fdzu tukov\u00e9 tk\u00e1n\u011b a m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed energetick\u00e9ho v\u00fddeje, kter\u00e9 peptidy pouze s GLP-1 neprodukuj\u00ed. V p\u0159\u00edm\u00fdch srovn\u00e1vac\u00edch studi\u00edch (SURPASS-2) dos\u00e1hl tirzepatid 15 mg lep\u0161\u00edho sn\u00ed\u017een\u00ed HbA1c a t\u011blesn\u00e9 hmotnosti oproti semaglutidu 1 mg za 40 t\u00fddn\u016f.<\/p>\n<h3>Jak se Tirzepatid li\u0161\u00ed od Retatrutidu?<\/h3>\n<p>Oba jsou zalo\u017eeny na GIP kost\u0159e, ale retatrutid nav\u00edc p\u0159id\u00e1v\u00e1 aktivitu glukagonov\u00e9ho receptoru krom\u011b GLP-1 a GIP \u2013 \u010d\u00edm\u017e se st\u00e1v\u00e1 trojit\u00fdm agonistou. P\u0159idan\u00e1 glukagonov\u00e1 slo\u017eka d\u00e1le p\u0159isp\u00edv\u00e1 k energetick\u00e9mu v\u00fddeji a lipol\u00fdze adipocyt\u016f. Publikovan\u00e1 data z f\u00e1ze 2 pro retatrutid ukazuj\u00ed sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti o ~24 % p\u0159i d\u00e1vce 12 mg t\u00fddn\u011b, co\u017e m\u00edrn\u011b p\u0159ekra\u010duje 22 % u tirzepatidu ve studii SURMOUNT-1. Tirzepatid m\u00e1 zralej\u0161\u00ed soubor klinick\u00fdch dat; retatrutid je st\u00e1le ve f\u00e1zi pozdn\u00edho v\u00fdvoje.<\/p>\n<h3>Jak\u00e1 je typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka Tirzepatidu?<\/h3>\n<p>Publikovan\u00e9 protokoly obvykle pou\u017e\u00edvaj\u00ed titra\u010dn\u00ed sch\u00e9ma za\u010d\u00ednaj\u00edc\u00ed na 2,5 mg t\u00fddn\u011b s postupn\u00fdm zvy\u0161ov\u00e1n\u00edm o 2,5 mg ka\u017ed\u00e9 4 t\u00fddny a\u017e na udr\u017eovac\u00ed d\u00e1vku 5\u201315 mg t\u00fddn\u011b. 10 mg lahvi\u010dka rekonstituovan\u00e1 s 2,0 mL bakteriostatick\u00e9 vody poskytne koncentraci 5 mg\/mL \u2013 10 d\u00edlek na U-100 st\u0159\u00edka\u010dce odpov\u00edd\u00e1 500 mcg.<\/p>\n<h3>Je Tirzepatid schv\u00e1len FDA?<\/h3>\n<p>Farmaceutick\u00fd tirzepatid je schv\u00e1len FDA pod obchodn\u00edmi n\u00e1zvy Mounjaro (diabetes 2. typu, 2022) a Zepbound (chronick\u00e1 kontrola hmotnosti, 2023), vyr\u00e1b\u011bn\u00fd podle standard\u016f GMP spole\u010dnost\u00ed Eli Lilly. V\u00fdzkumn\u00fd tirzepatid prod\u00e1van\u00fd zde je samostatn\u00fd produkt ur\u010den\u00fd pouze pro laboratorn\u00ed v\u00fdzkum a nen\u00ed <strong>ne<\/strong> schv\u00e1len FDA pro lidsk\u00e9 nebo veterin\u00e1rn\u00ed pou\u017eit\u00ed. Nesm\u00ed b\u00fdt pod\u00e1v\u00e1n lidem ani zv\u00ed\u0159at\u016fm.<\/p>\n<h3>Jak by m\u011bl b\u00fdt Tirzepatid skladov\u00e1n?<\/h3>\n<p>Lyofilizovan\u00e9 lahvi\u010dky: kr\u00e1tkodob\u011b skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, dlouhodob\u011b neotev\u0159en\u00e9 lahvi\u010dky p\u0159i \u221220 \u00b0C. Rekonstituovan\u00fd roztok: skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. Rekonstituovan\u00fd roztok nezmrazujte \u2014 mrazic\u00ed cykly degraduj\u00ed peptid. V\u017edy chra\u0148te p\u0159ed p\u0159\u00edm\u00fdm sv\u011btlem.<\/p>\n<h3>Jak rekonstituovat Tirzepatid?<\/h3>\n<p>Postupujte podle v\u00fd\u0161e uveden\u00e9ho rekonstitu\u010dn\u00edho postupu. P\u0159idejte bakteriostatickou vodu po st\u011bn\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovan\u00fd pr\u00e1\u0161ek), jemn\u011b prot\u0159epejte a nechte 2\u20135 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed. Ne <strong>ne<\/strong> prot\u0159ep\u00e1vejte lahvi\u010dku. Spr\u00e1vn\u011b rekonstituovan\u00fd roztok je \u010dir\u00fd a bezbarv\u00fd. Pro lahvi\u010dku 10 mg + 2,0 ml rozpou\u0161t\u011bdla je pracovn\u00ed koncentrace 5 mg\/ml.<\/p>\n<h3>Jak\u00e9 s\u00edly nab\u00edz\u00ed MedsBase?<\/h3>\n<p>MedsBase nab\u00edz\u00ed Tirzepatid v jeden\u00e1cti lyofilizovan\u00fdch d\u00e1vk\u00e1ch: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg a 120 mg. Ka\u017ed\u00e1 d\u00e1vka je dostupn\u00e1 v balen\u00ed po 10 nebo 20 lahvi\u010dk\u00e1ch. V\u0161echny lahvi\u010dky maj\u00ed HPLC \u010distotu 99 %+ a certifik\u00e1t anal\u00fdzy je k dispozici na vy\u017e\u00e1d\u00e1n\u00ed.<\/p>\n<h3>Jak\u00fd je polo\u010das Tirzepatidu?<\/h3>\n<p>Tirzepatid m\u00e1 po subkut\u00e1nn\u00edm pod\u00e1n\u00ed plazmatick\u00fd polo\u010das p\u0159ibli\u017en\u011b 120 hodin (~5 dn\u00ed). Tento polo\u010das je dosa\u017een reverzibiln\u00ed vazbou na cirkuluj\u00edc\u00ed s\u00e9rov\u00fd albumin prost\u0159ednictv\u00edm C20 mastn\u00e9ho diacylov\u00e9ho \u0159et\u011bzce na lysinu 20, kter\u00fd chr\u00e1n\u00ed peptid p\u0159ed ren\u00e1ln\u00ed clearance. V kombinaci s dvojitou substituc\u00ed Aib (pozice 2 a 13), kter\u00e1 blokuje \u0161t\u011bpen\u00ed DPP-4, to umo\u017e\u0148uje t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed srovnateln\u00e9 s polo\u010dasem semaglutidu ~165 hodin.<\/p>\n<h3>Pro\u010d Tirzepatid zp\u016fsobuje v\u011bt\u0161\u00ed \u00fabytek hmotnosti ne\u017e Semaglutid?<\/h3>\n<p>Nej\u010dast\u011bji uv\u00e1d\u011bn\u00fdm mechanismem je slo\u017eka GIP-receptoru. Aktivace GIP-receptoru p\u0159in\u00e1\u0161\u00ed dal\u0161\u00ed efekty, kter\u00e9 samotn\u00fd GLP-1 nevyvol\u00e1v\u00e1: zv\u00fd\u0161enou lipol\u00fdzu adipocyt\u016f p\u0159i hladov\u011bn\u00ed, m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed klidov\u00e9ho energetick\u00e9ho v\u00fddeje a \u00fa\u010dinky na CNS v dorzomedi\u00e1ln\u00edm hypotalamu odli\u0161n\u00e9 od signalizace GLP-1 v arcu\u00e1tn\u00edm j\u00e1dru. Kombinovan\u00fd dvojit\u00fd sign\u00e1l vede k aditivn\u00edmu sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti oproti samotn\u00e9mu GLP-1 ve srovn\u00e1vac\u00edch v\u00fdzkumn\u00fdch modelech.<\/p>\n<h3>Zp\u016fsobuje Tirzepatid ve v\u00fdzkumu vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Nejkonzistentn\u011bj\u0161\u00edm n\u00e1lezem jsou gastrointestin\u00e1ln\u00ed \u00fa\u010dinky \u2014 nauzea, p\u0159echodn\u00e9 potla\u010den\u00ed chuti k j\u00eddlu a opo\u017ed\u011bn\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku jsou z\u00e1visl\u00e9 na d\u00e1vce a maj\u00ed tendenci se zm\u00edr\u0148ovat po 4\u20138 t\u00fddnech kontinu\u00e1ln\u00edho pod\u00e1v\u00e1n\u00ed, jak se vyv\u00edj\u00ed tachyfylaxe receptor\u016f. M\u00e9n\u011b \u010dast\u00e9 n\u00e1lezy zahrnuj\u00ed \u00fa\u010dinky na motilitu \u017elu\u010dn\u00edku a (u hlodavc\u016f s citlivost\u00ed C-bun\u011bk \u0161t\u00edtn\u00e9 \u017el\u00e1zy) hyperplazii C-bun\u011bk \u2014 posledn\u00ed jmenovan\u00e9 je druhov\u011b specifick\u00fd sign\u00e1l, kter\u00fd se v dlouhodob\u00e9m klinick\u00e9m sledov\u00e1n\u00ed u lid\u00ed neprok\u00e1zal.<\/p>\n<h3>Lze Tirzepatid a Semaglutid ve v\u00fdzkumu srovn\u00e1vat?<\/h3>\n<p>Ano \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed je jednou z nejintenzivn\u011bji studovan\u00fdch ot\u00e1zek v inkretinov\u00e9 farmakologii. Klinick\u00e1 studie SURPASS-2 p\u0159\u00edmo porovn\u00e1vala tirzepatid 15 mg se semaglutidem 1 mg u pacient\u016f s diabetem 2. typu; preklinick\u00e9 a rostouc\u00ed re\u00e1ln\u00e9 d\u016fkazy d\u00e1le roz\u0161i\u0159uj\u00ed toto srovn\u00e1n\u00ed na t\u011blesnou hmotnost, MASH a kardiovaskul\u00e1rn\u00ed parametry. Semaglutid z\u016fst\u00e1v\u00e1 standardn\u00edm kompar\u00e1torem GLP-1; tirzepatid je standardn\u00edm kompar\u00e1torem du\u00e1ln\u00edho agonismu.<\/p>\n<h3>Jak dlouho trv\u00e1, ne\u017e se \u00fa\u010dinky tirzepatidu projev\u00ed v preklinick\u00e9m v\u00fdzkumu?<\/h3>\n<p>Akutn\u00ed farmakodynamick\u00e9 \u00fa\u010dinky na gluk\u00f3zovou toleranci a vyprazd\u0148ov\u00e1n\u00ed \u017ealudku jsou detekovateln\u00e9 ji\u017e b\u011bhem n\u011bkolika hodin po prvn\u00ed d\u00e1vce. \u00da\u010dinky na t\u011blesnou hmotnost u ob\u00e9zn\u00edch hlodavc\u016f se obvykle st\u00e1vaj\u00ed statisticky v\u00fdznamn\u00fdmi po 1\u20132 t\u00fddnech t\u00fddenn\u00edho pod\u00e1v\u00e1n\u00ed a d\u00e1le se zvy\u0161uj\u00ed po dobu 8\u201316 t\u00fddn\u016f. Maxim\u00e1ln\u00ed \u00fa\u010dinek na t\u011blesn\u00e9 slo\u017een\u00ed je obvykle pozorov\u00e1n po 16\u201324 t\u00fddnech kontinu\u00e1ln\u00edho pod\u00e1v\u00e1n\u00ed ve v\u00fdzkumn\u00fdch modelech, co\u017e odpov\u00edd\u00e1 trajektorii u lidsk\u00fdch studi\u00ed.<\/p>\n<h3>Mohu si objednat tirzepatid pro mezin\u00e1rodn\u00ed p\u0159epravu?<\/h3>\n<p>Ano. MedsBase expeduje tirzepatid do cel\u00e9ho sv\u011bta prost\u0159ednictv\u00edm na\u0161\u00ed specializovan\u00e9 s\u00edt\u011b pro p\u0159epravu peptid\u016f. Objedn\u00e1vky obsahuj\u00edc\u00ed pouze peptidy jsou zp\u016fsobil\u00e9 pro na\u0161i samostatnou slu\u017ebu p\u0159epravy peptid\u016f. V\u0161echny objedn\u00e1vky jsou expedov\u00e1ny v teplotn\u011b kontrolovan\u00e9m balen\u00ed s pln\u00fdm sledov\u00e1n\u00edm a jsou pokryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro v\u00fdzkum metabolismu a t\u011blesn\u00e9ho slo\u017een\u00ed<\/h2>\n<ul>\n<li><a href=\"\/cs\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Jednoduch\u00fd agonista GLP-1 (aktivn\u00ed l\u00e1tka Ozempic\/Wegovy\/Rybelsus) \u2014 standardn\u00ed kompar\u00e1tor pro v\u00fdzkum glyk\u00e9mie a kardiovaskul\u00e1rn\u00edho syst\u00e9mu<\/li>\n<li><a href=\"\/cs\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Trojit\u00fd agonista GLP-1\/GIP\/glukagon \u2014 nov\u00e1 generace v\u00fdzkumu v\u00edceos\u00e9ho metabolismu<\/li>\n<li><a href=\"\/cs\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analog GHRH \u2014 v\u00fdzkum viscer\u00e1ln\u00ed tukov\u00e9 tk\u00e1n\u011b<\/li>\n<li><a href=\"\/cs\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondri\u00e1ln\u011b k\u00f3dovan\u00fd peptid napodobuj\u00edc\u00ed cvi\u010den\u00ed \u2014 v\u00fdzkum AMPK a inzulinov\u00e9 senzitivity<\/li>\n<li><a href=\"\/cs\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Dlouhodob\u011b p\u016fsob\u00edc\u00ed analog GHRH pro v\u00fdzkum r\u016fstov\u00e9 osy<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Dal\u0161\u00ed \u010dten\u00ed<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Porovnejte dlouhodob\u011b p\u016fsob\u00edc\u00ed inkretinov\u00e9 p\u0159\u00edpravky<\/strong><\/p>\n<p style=\"margin: 0;\">P\u0159e\u010dt\u011bte si na\u0161e p\u0159\u00edm\u00e9 srovn\u00e1vac\u00ed pr\u016fvodce: <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-vs-tirzepatide\/\"><strong>Retatrutid vs Tirzepatid \u2014 trojit\u00fd vs dvojit\u00fd agonista<\/strong><\/a> a <a href=\"https:\/\/medsbase.com\/cs\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. Pokr\u00fdv\u00e1 farmakologii receptor\u016f, in\u017een\u00fdrstv\u00ed sekvenc\u00ed, polo\u010das rozpadu, d\u00e1vkovou odezvu a data ze srovn\u00e1vac\u00edch studi\u00ed, kter\u00e9 odli\u0161uj\u00ed tirzepatid od semaglutidu (SURPASS-2) a v\u00fdsledky f\u00e1ze 2 u retatrutidu jako\u017eto trojit\u00e9ho agonisty.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Dvojit\u00fd ko-agonista receptor\u016f GLP-1 + GIP<br \/>\n\u2705 Nejv\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost u jednoho peptidu<br \/>\n\u2705 Podporuje v\u00fdzkum glykemick\u00e9 kontroly<br \/>\n\u2705 Lipol\u00fdza adipocyt\u016f a energetick\u00fd v\u00fddej<br \/>\n\u2705 Jednou t\u00fddn\u011b d\u00e1vkovac\u00ed protokoly<\/p>\n<p><strong>Tirzepatide<\/strong> obsahuje syntetickou peptidovou slou\u010deninu.<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":{"0":"post-70674","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-peptide","8":"product_tag-tirzepatide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}